Side-by-side comparison of AI visibility scores, market position, and capabilities
Vancouver-based antibody discovery platform with 104+ partner programs; $75M FY2025 revenue. Expanding into wholly owned assets with ABCL635 in Phase 1 for vasomotor symptoms.
AbCellera Biologics was founded in 2012 in Vancouver, Canada by Carl Hansen, growing out of research at the University of British Columbia. The company built a high-throughput antibody discovery platform integrating microfluidics, genomics, single-cell sequencing, and AI/ML to rapidly identify therapeutic antibody candidates from natural immune responses. AbCellera played a prominent role in the COVID-19 pandemic by discovering bamlanivimab for Eli Lilly in under 90 days.\n\nAbCellera's partnership model operates on a discovery fee plus downstream milestone and royalty structure, having started over 104 partner-initiated programs with downstream participation as of December 2025. Partners include major pharmaceutical companies and biotechs; the company expanded its collaboration with AbbVie in 2025 to develop T-cell engagers for oncology. Total FY2025 revenue was $75 million ($47M from royalties/licensing, $27M from partnered program work), compared to $29 million in 2024—a dramatic increase driven by royalty flows from approved medicines.\n\nIn 2025 AbCellera began transitioning from pure partnership model toward wholly owned therapeutic assets, with ABCL635 (a GnRH receptor antibody for vasomotor symptoms) entering Phase 1. The company maintains approximately $700 million in liquidity, providing a long runway. AbCellera is considered a foundational infrastructure provider for the antibody-based drug discovery ecosystem.
2024 Revenue: KRW 175.2T (+7.7% YoY) | Operating Profit: KRW 14.2T (-5.9%) | Vehicle Sales: 4.14M units (-1.8%) | Q4 2024: Revenue KRW 46.62T (+11.9%), Op Profit KRW 2.82T (-17.2%) | Electrified Vehicles: 757k units (+8.9%, 21.8% of sales) | US Market: 988k units (+9%) | 2025 guidance: 3-4% revenue growth, 7-8% op margin
Hyundai Motor Company was founded in 1967 in Seoul, South Korea, by Chung Ju-yung and has grown into one of the world's largest automotive manufacturers, ranking third globally by vehicle sales. From its origins as a budget-focused automaker producing affordable, practical vehicles for emerging markets, Hyundai has transformed over the past two decades into a technology-forward brand competing directly with European and Japanese premium manufacturers. Its mission centers on delivering smart mobility solutions for a sustainable future.\n\nHyundai's product lineup spans mass-market sedans, SUVs, and commercial vehicles, alongside its premium Genesis brand and the Ioniq dedicated EV lineup. The Ioniq 5, Ioniq 6, and Ioniq 7 have emerged as critically acclaimed electric vehicles, with the Ioniq 5 winning the World Car of the Year award. Hyundai is also investing heavily in hydrogen fuel cell technology, autonomous driving, and robotics through subsidiaries including Boston Dynamics. Its vehicles are sold in over 200 countries through a network of more than 6,000 dealerships.\n\nHyundai reported revenue of KRW 175.2 trillion in 2024, a 7.7% year-over-year increase, with Q4 2024 revenue of KRW 46.62T (+11.9%). The company sold 4.14M vehicles globally in 2024. With major EV manufacturing investments underway in the United States (Metaplant America in Georgia), Hyundai is positioning itself to be a top-three EV manufacturer globally by 2030, backed by robust R&D spending and a vertically integrated battery and platform strategy.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.